Brought to you by 
Brickell enters $25mm financing agreement with NovaQuest
04 Jun 2019
Executive Summary
NovaQuest Capital Management committed up to $25mm in near-term research and development funding to Brickell Biotech Inc. following the closing of Brickell's concurrent reverse merger with Vical Inc., which will hold a 40% stake in the combined company.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Preliminary
Deal Type
-
Financing
- Other
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Brickell enters $25mm financing agreement with NovaQuest
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice